- PALB2 mutation as a predictive biomarker for immunotherapy in patients with advanced melanoma: Results from (a pooled analysis of) five multicenter, randomized clinical trials.You, Changxuan; Zheng, Yating; Huang, MengliVirtual Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 2021-06-04 To 2021-06-08.被引 1
- DNA damage repair gene mutations predict the efficacy of immunization combined with platinum chemotherapy in advanced non-small cell lung cancer: A retrospective cohort studyXiao, Zhiwe; Sun, Lingling; Zheng, Yating; Chen, Hanrui; Zheng, Xinting; Luo, Jiamin; Gu, Chuying; Lin, Ruiting; Hu, Xue; Huang, Mengli; Lin, LizhuAnnual Meeting of the American-Association-for-Cancer-Research (AACR), New Orleans, LA, 2022-04-08 To 2022-04-13.
- DNA damage repair gene mutations predict the efficacy of immunization combined with platinum chemotherapy in advanced non-small cell lung cancer: A retrospective cohort study.Xiao, Zhiwe; Sun, Lingling; Zheng, Yating; Chen, Hanrui; Zheng, Xinting; Luo, Jiamin; Gu, Chuying; Lin, Ruiting; Hu, Xue; Huang, Mengli; Lin, LizhuAnnual Meeting of the American-Association-for-Cancer-Research (AACR), New Orleans, LA, 2022-04-08 To 2022-04-13.
会议论文
Correlation between homologous recombination repair gene mutation and immunotherapy efficacy in patients with advanced melanoma.
6阅读
